[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"continuous-glucose-monitoring\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:continuous-glucose-monitoring":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,45,69,96,145,175,208,241,274,292,316,338,362,385],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100512089","real-time-continuous-glucose-monitoring-system-in-t2dm-with-pregnacy-100512089",false,"NCT05947916","Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy","Effect of Real Time Continuous Glucose Monitoring System on Management of Women With Type 2 Diabetes Mellitus During Pregnancy in a Multidisciplinary Comprehensive System","Inclusion Criteria:\n\n* A clear history of type 2 diabetes, or a history of type 2 diabetes diagnosed in early pregnancy\n* Singleton gestation at 4-26 weeks, with substandard glycemic control (i.e., fasting glucose \\> 5.3 mmol\u002FL, and or 1 hour postprandial glucose \\> 7.8 mmol\u002FL, and or 2 hours postprandial glucose \\> 6.7 mmol\u002FL) after lifestyle intervention ± basal insulin therapy, as assessed by the endocrinology department. Patients who need insulin regimen with basal plus meal or insulin pump regimen.\n* Patients are willing and committed to establish and follow up in the obstetrics and gynecology departments of Peking University Third Hospital, Haidian District Hospital and Yanqing District Hospital during pregnancy, and are willing to provide information on obstetric examination and perinatal medical records if they are transferred to the hospital for special reasons for follow-up or delivery.\n* Voluntarily participate in the study, examine and follow up according to this project and sign informed consent.\n* Able to pass the screening period Adherence evaluation\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, specific type of diabetes or gestational diabetes\n* Pregnancy with severe comorbidities or diabetic complications for which obstetrics does not recommend continuation of pregnancy, including but not limited to the following: proliferative retinopathy, chronic kidney disease (eGFR less than 60 mL\u002Fmin\u002F1.73± massive proteinuria), known coronary and cerebrovascular disease, autoimmune system disease and receiving exogenous glucocorticoids or immunosuppressive therapy.\n* Patients who have been hospitalized for psychiatric treatment within 6 months prior to enrollment or are still on psychiatric medications.\n* Patients who have received other interventional studies.","FEMALE","18 Years","40 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","The prevalence of type 2 diabetes mellitus (T2DM) in women of childbearing age is increasing rapidly, and low glucose compliance leads to an increased risk of adverse pregnancy outcomes for mothers and infants during pregnancy in women with T2DM. Real-time continuous glucose monitoring (CGM) is an important tool for glucose monitoring and patient education, as it can continuously record blood glucose throughout the day and provide real-time feedback on high and low blood glucose levels. This is a multicenter, open-label, randomized controlled clinical study to investigate the efficacy, safety, and maternal and infant pregnancy outcomes of using real-time CGM monitoring compared with conventional self-monitoring of blood glucose (SMBG) on the basis of multidisciplinary management in pregnant women with T2DM. One hundred and twenty pregnant women with T2DM in early pregnancy who were enrolled in intensive insulin therapy were randomly divided into the real-time CGM group and the conventional SMBG group. The real-time CGM intervention group wore real-time CGM for more than 50% of the pregnancy in addition to regular SMBG; the control group only performed regular SMBG. Both groups wore Medtronic iPro 2 for 3 days in early, mid and late pregnancy, and the time in the target range of blood glucose (TIR) was recorded in a blinded manner. Primary outcome: differences in TIR between the two groups of pregnant women in early, mid, and late pregnancy. Secondary outcomes included differences in glycated hemoglobin, hypoglycemia, insulin dose before delivery, pregnancy weight gain, and maternal and infant pregnancy outcomes.",[27,28,29,30,31],"Type2diabetes","Pregnancy Related","Continuous Glucose Monitoring","Time in Range","Pregnancy Outcome","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2024-01-30",{"date":40,"type":21},"2026-12-31",{"name":42,"class":43},"Peking University Third Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100549615","the-impact-of-continuous-glucose-monitoring-on-maternal-and-infants-outcomes-in-gestational-diabetes-100549615","NCT06436326","The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes","The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes: Testing the Moderating Effects of Socioeconomic and Cultural Factors","Inclusion Criteria:\n\n* Aged 18 years or above\n* Pregnant women diagnosed with gestational diabetes mellitus\n* Those who are willing to participate in this study\n\nExclusion Criteria:\n\n* Those who have been diagnosed with diabetes mellitus \"before pregnancy\"\n* Those whose skin is likely allergic to some materials such as tapes (signs and symptoms such as redness, swelling, itching, painful, presenting blisters or rashes caused by wearing breathable tapes, patches, etc.)\n* Those who is with abnormal coagulation function",{"count":53,"type":21},120,[24],"This study will discuss the impact of continuous glucose monitoring on maternal and infant's outcomes in gestational diabetes mellitus, and test the moderating effect of socioeconomic and cultural factors (dietary habits, socioeconomic status and income).",[57,29],"Gestational Diabetes Mellitus",[57,29,59],"Health Interventions","2026-06-17",{"date":62,"type":36},"2026-06-22",{"date":64,"type":36},"2024-08-22",{"date":66,"type":21},"2027-12-31",{"name":68,"class":43},"National Taiwan University Hospital",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":77,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100638260","metabolic-control-in-anesthesia-and-surgery-100638260","NCT07573930","Metabolic Control in Anesthesia and Surgery","Deteriorated Metabolic Control in the Perioperative Period in Surgical Patients: What is the Impact of Anesthetic Preparation and Patient Frailty?","MACS","Inclusion Criteria:\n\n* Adult patients (≥18 years) scheduled for elective non cardiac surgery\n* Expected surgery duration \\>1 hour\n* Administration of dexamethasone as part of standard anaesthetic regimen or planned by the responsible anaesthetist to enhance recovery or to limit risk of PONV.\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Not possible to obtain consent or permission\n* Known allergy or adverse reaction to dexamethasone\n* Type 1 diabetes (due to need for insulin titration)\n* Active infection, sepsis, or immunosuppression\n* Contraindications to continuous glucose monitoring (CGM)","ALL",{"count":79,"type":21},100,"OBSERVATIONAL","The goal of this observational study is to investigate how a standard dose of the drug dexamethasone affects blood sugar levels during and after non-cardiac surgery in adult patients.\n\nThe main questions it aims to answer are:\n\n* How does dexamethasone influence blood sugar levels in patients undergoing non-cardiac surgery?\n* Does continuous glucose monitoring (CGM) provide a more accurate estimate of blood sugar fluctuations compared to traditional time-specific finger-prick measurements?\n\nParticipants are scheduled to receive dexamethasone as part of standard anesthesia care and will undergo their planned surgery. As part of the study, a continuous glucose monitoring (CGM) device will be placed on their upper arm approximately 12 hours before surgery and will remain in place for up to 10 days after the operation. During this period, their blood sugar levels will be measured using both the CGM device and traditional finger-prick tests. CGM readings are blinded for both participants and clinicians. No additional treatments or changes to their standard care will be made as a result of their participation in the study.\n\nThe study will include 100 adult patients from the Department of Anesthesiology at Sjællands University Hospital, Roskilde.",[83,29,84,85,86],"Anesthesia","Hyperglycemia Steroid-induced","Hyperglycemia Stress","Surgical Procedure, Unspecified","2026-05-04",{"date":89,"type":36},"2026-05-07",{"date":91,"type":36},"2026-04-23",{"date":93,"type":21},"2028-12-31",{"name":95,"class":43},"Zealand University Hospital",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":16,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":127,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":44},"100634052","early-pregnancy-lifestyle-and-glucose-patterns-a-substudy-of-tofffy-100634052","NCT07534670","Early Pregnancy Lifestyle and Glucose Patterns: A Substudy of TOFFFY","Early-Pregnancy Chronobehavioural Profiles and Continuous Glucose Dynamics: A Nested Randomised Pilot Study of TOFFFY","Inclusion Criteria:\n\n* Enrolled in the Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) (NCT06293235)\n* Females who are currently pregnant and with viable intrauterine pregnancy at ≤13 weeks gestation at enrolment\n\nExclusion Criteria:\n\n* Females with pre-existing diabetes mellitus (Type 1 or Type 2) and\u002For chronic medical conditions affecting glucose metabolism\n* Females who are taking medications known to significantly affect glucose metabolism\n* Females with multiple pregnancy (e.g., twins or higher-order gestation)\n* Females who are unable to comply with study procedures, including: Inability to use smartphone-based applications and inability to wear wrist actigraphy device",true,"21 Years","39 Years",{"count":107,"type":21},140,[24],"The goal of this clinical trial is to examine how daily behavioral patterns in early pregnancy, including sleep, physical activity, and meal timing, influence continuous glucose dynamics and subsequent risk of gestational diabetes mellitus (GDM) in pregnant women without pre-existing diabetes.\n\nThe main questions it aims to answer are:\n\n1. Do early-pregnancy chronobehavioral patterns (e.g., irregular sleep, night eating, and unstable rest-activity rhythms) relate to continuous glucose patterns measured using continuous glucose monitoring (CGM)?\n2. Can early behavioral and CGM-derived measures predict glucose regulation and metabolic outcomes later in pregnancy (24-28 weeks)?\n3. Does real-time self-monitoring using wearable devices and food logging improve glycemic outcomes compared to usual care?\n\nThis study is a prospective, nested randomized pilot trial embedded within the ongoing Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) cohort (NCT06293235) at KK Women's and Children's Hospital, Singapore. A total of 140 pregnant women without pre-existing diabetes, recruited at ≤13 weeks gestation, will be randomized in a 1:1 ratio to either a pilot arm (wearable-based self-monitoring) or a control arm (usual care).\n\nParticipants in the pilot arm (n=70) will undergo intensive behavioral and metabolic monitoring over a 14-day period in early pregnancy, including continuous glucose monitoring using a CGM device, wrist actigraphy to assess sleep-wake and rest-activity patterns, and an AI-supported mobile application to record meal timing and dietary intake. Participants will have real-time access to their glucose data and behavioral feedback, enabling self-monitoring and potential behavioral adjustments.",[29,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126],"Diabetes, Gestational","Diet During Pregnancy","Meal Time","Actigraphy","Pregnancy","Glucose Intolerance During Pregnancy","Gestational Diabetes Mellitus in Pregnancy","Circadian Rhythm","Sleep","Chronobiology","Wearable Electronic Devices","Mobile Applications","Blood Glucose Profile","Metabolic Diseases","Randomized Controlled Trial","Pilot Study",[128,129,130,131,132,133],"Risk factor","Lifestyle","Early pregnancy","Chrono-disruptive behaviours","Maternal health","Lifestyle intervention","NOT_YET_RECRUITING","2026-04-22",{"date":137,"type":36},"2026-04-27",{"date":139,"type":21},"2026-05-01",{"date":141,"type":21},"2027-06-30",{"name":143,"class":144},"KK Women's and Children's Hospital","OTHER_GOV",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":160,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":44},"100630134","glucose-profiles-in-women-with-polycystic-ovary-syndrome-100630134","NCT07483723","Glucose Profiles in Women With Polycystic Ovary Syndrome","PROGLYSOPK","Inclusion Criteria:\n\n* Age \\> 18 years at inclusion criteria\n* Patient with polycystic ovary syndrome, defined by the presence of at least 2\u002F3 irregular menstrual cycles, clinical or biological hyperandrogenism, polycystic ovary morphology (pelvic ultrasound) or elevated AMH levels, after the exclusion of other disorders.\n* Agreed to carry the FSL pro\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnancy, breast-feeding\n* Differential diagnoses: hyperprolactinemia, dysthyroidism, Cushing's syndrome, congenital adrenal hyperplasia, virilizing tumor (ovarian or adrenal), intake of exogenous androgens\n* Pre-existing diabetes\n* Patient treated within 3 months prior to inclusion\u002Fdata collection with estrogen-progestin contraception, progestin contraception, antidiabetic drugs, inositol, antiandrogen",{"count":153,"type":21},80,[24],"Polycystic ovary syndrome is a very common condition that is associated with metabolic complications. Patients with polycystic ovary syndrome exhibit insulin resistance and are at greater risk to develop type 2 diabetes. This syndrome is heterogeneous, classified according to 4 phenotypes (A-D). It seems that certain phenotypes are less exposed to insulin resistance and metabolic complications. However, only a few studies have evaluated the glucose profile according to phenotype. New technologies now make it possible to monitor glucose levels continuously. The aim of this project is to evaluate glucose profile parameters using continuous glucose monitoring, and to compare these profiles according to different PCOS phenotypes.",[157,158,159,29],"Polycystic Ovary Syndrome","Glucose Profile","Insulin Resistance",[161,162,163,164,165],"polycystic ovary syndrome","phenotype","glucose profile","insulin resistance","continuous glucose monitoring","2026-03-17",{"date":168,"type":36},"2026-03-19",{"date":170,"type":36},"2026-01-06",{"date":172,"type":21},"2027-07",{"name":174,"class":43},"Centre Hospitalier Universitaire, Amiens",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":77,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":194,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":44},"100613701","pilot-testing-real-time-engagement-for-learning-to-effectively-control-type-2-diabetes-100613701","NCT07270016","Pilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes","Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes: Pilot Study","REFLECT2DPilot","Inclusion criteria:\n\n* Ages 16-24 years, any sex or gender\n* Diagnosis of type 2 diabetes in childhood (younger than 18 years of age)\n* English-speaking (app in English)\n* Possession of personal smartphone that is compatible with FreeStyle Libre app\n\nExclusion Criteria:\n\n• Cognitive impairment or severe psychiatric conditions that could interfere with participation in behavioral intervention for diabetes self-management","16 Years","24 Years",{"count":186,"type":21},30,[24],"The goal of this study is to pilot test features of a new smartphone app and to gather feedback related to wearing a continuous glucose monitor (CGM) and a Fitbit device, as well as to obtain input on health behavior-focused messages delivered through the app. The study will enroll English-speaking participants aged 16-24 years who were diagnosed with type 2 diabetes before age 18. Participants will be asked to fill out surveys about diabetes, physical activity, and diet before and after wearing a CGM for 30 days. At the end of wearing the CGM, participants will complete an interview about their experience.",[190,191,192,193,29],"Diabetes Mellitus, Type 2","Hyperglycemia","Physical Inactivity","Lifestyle (Sedentary Behavior and Physical Activity)",[195,196,197,198],"adolescent","young adult","type 2 diabetes","CGM","2026-02-18",{"date":201,"type":36},"2026-02-20",{"date":203,"type":36},"2026-02-16",{"date":205,"type":21},"2026-12",{"name":207,"class":43},"University of Pittsburgh",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":77,"minAge":17,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":44},"100597654","transition-to-hospital-discharge-in-insulinized-patients-with-type-2-diabetes-mellitus-100597654","NCT07061301","Transition to Hospital Discharge in Insulinized Patients With Type 2 Diabetes Mellitus","Transition to Hospital Discharge in Insulinized Patients With Type 2 Diabetes Mellitus and Incorporation Into a Comprehensive Diabetes Management System","TRANHOSPIN","Inclusion Criteria:\n\n* Adults aged 18 to 70 years.\n* Hospitalized patients with a diagnosis of type 2 diabetes mellitus (T2DM), either newly diagnosed during admission or previously known but not previously treated with insulin.\n* Initiation of insulin therapy (basal, basal-plus, or basal-bolus regimen) during hospitalization, with planned continuation post-discharge.\n* Independent in basic activities of daily living.\n* Adequate cognitive and functional capacity to manage the required devices: insulin pen, glucometer, continuous glucose monitoring (CGM) sensor, and Insulclock® cap.\n\nExclusion Criteria:\n\n* Dependence in basic activities of daily living.\n* Any medical condition or functional limitation precluding the use of the CGM or the Insulclock® system.\n* Pregnancy or intention to become pregnant.\n* Diagnosis of type 1 diabetes mellitus.\n* Patients undergoing dialysis.","70 Years",{"count":153,"type":21},[24],"This clinical study explores whether adding technological tools during hospital discharge can help people with type 2 diabetes who are starting insulin therapy achieve better treatment adherence and blood glucose control once they return home. The discharge transition period includes both the final days of hospitalization and the first weeks to months after returning home.\n\nWhen people with type 2 diabetes are hospitalized, they sometimes need to begin insulin therapy. After discharge, managing insulin properly is essential to avoid high or low blood sugar levels. However, many patients forget or delay insulin doses, which can lead to poor control of their diabetes.\n\nThis study will compare two groups of patients. All participants will be adults with type 2 diabetes, between 18 and 70 years old, who are newly starting insulin during their hospital stay.\n\nGroup 1 (\"technological group\") will use a continuous glucose monitor (CGM) and a smart insulin pen cap called Insulclock. These tools show real-time blood glucose data and record when and how much insulin is injected. Patients and doctors can use this information to better adjust treatment. Insulclock also includes alarms to remind patients of their doses.\n\nGroup 2 (\"control group\") will use the same devices, but they will not see the data in real time. Instead, they will manage their insulin based on standard finger-prick blood sugar checks four times a day, as typically done in standard care.\n\nBoth groups will be followed for 12 weeks after hospital discharge. Medical check-ins will occur in weeks 1, 2, 4, 8, and 12. Blood tests and treatment adjustments will be performed as needed.\n\nThe main goals are:\n\nTo measure if the use of technology helps patients stick to their insulin schedule (fewer missed or mistimed injections).\n\nTo see if it leads to better blood glucose control (e.g., more time within the recommended range, fewer episodes of low or high glucose).\n\nTo evaluate patient satisfaction with this technology and check if the number of unplanned hospital readmissions decreases.\n\nThe study will take place at Hospital Universitari i Politècnic La Fe in Valencia, Spain. Around 80 patients will participate.\n\nThis study is important because real-world data about the use of CGM and smart insulin devices during the hospital-to-home transition are limited. It may help improve diabetes care for people starting insulin after hospitalization.",[221,29,198,222,223],"Type 2 Diabetes Mellitus (T2DM)","Transition to Discharge","Smart Insulin Pen Cap",[225,226,227,228,229,230,231],"Type 2 Diabetes Mellitus","cgm","Continuous glucose monitoring","Transition to discharge","smart insulin pen cap","discharge","Insulinized patients","2026-01-22",{"date":234,"type":36},"2026-01-23",{"date":236,"type":36},"2024-08-01",{"date":238,"type":21},"2026-07",{"name":240,"class":43},"Instituto de Investigacion Sanitaria La Fe",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":77,"minAge":247,"maxAge":216,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":258,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":272,"locationsCount":44},"100621192","risks-of-ramadan-fasting-in-patients-with-primary-adrenal-insufficiency-treated-with-prednisolone-100621192","NCT07367425","Risks of Ramadan Fasting in Patients With Primary Adrenal Insufficiency Treated With Prednisolone.","Inclusion Criteria:\n\n* subjects with primary adrenal insufficiency known for at least one year, treated with a glucocorticoid and a mineralocorticoid, who wish to fast during Ramadan 2026.\n\nExclusion Criteria:\n\n* presence of diabetes, renal, hepatic, cardiac, or respiratory insufficiency; use of hypoglycemic agents (sulfonylureas), diuretics, use of any glucocorticoid other than the prescribed replacement therapy; poor disease control (asthenia, malaise, hyperpigmentation, discontinuation of treatment, etc.); pregnancy; breastfeeding; menstruation.","20 Years",{"count":249,"type":21},35,[24],"In primary adrenal insufficiency (PAI), there is a risk of hypoglycemia and dehydration. These risks seem to be increased during intermittent fasting. A previous study in patients with PAI treated with hydrocortisone at a dose of 20 mg\u002Fday showed that the prevalence of hypoglycemia was as high outside (63%) as during Ramadan fasting (71%), and that there was no risk of dehydration. We propose to evaluate the risk of complications during and outside of Ramadan fasting through a prospective study with subjects taken as their own controls, in 35 patients with PAI treated with prednisolone at a dose of 5 mg\u002Fday. Patients will undergo an interview, physical examination, blood sampling, and continuous glucose monitoring (CGM) during two weeks of fasting and two weeks of non-fasting.",[253,254,255,29,256,257],"Primary Adrenal Insufficiency","Ramadan Fasting","Prednisolone","Hypoglycemia Non-Diabetic","Dehydration",[259,260,165,261,262,263,264,265],"primary adrenal insufficiency","Ramadan fasting","hypoglycemia","dehydration","glucocorticoid replacement therapy","prednisolone","hypotension","2026-01-16",{"date":268,"type":36},"2026-01-26",{"date":232,"type":21},{"date":271,"type":21},"2026-03-30",{"name":273,"class":43},"Hopital La Rabta",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":291,"locationsCount":44},"100565899","the-project-for-managing-cardiometabolic-risk-in-women-diagnosed-with-gestational-diabetes-mellitus-100565899","NCT06648174","The Project for Managing Cardiometabolic Risk in Women Diagnosed With Gestational Diabetes Mellitus","The Project for Managing Cardiometabolic Risk in Women Diagnosed With Gestational Diabetes Mellitus: The Development and Application of \"a Lifestyle Intervention Based on Health Belief Model Supported by Mobile Health\"","Inclusion Criteria:\n\n1. Aged 18 years or above\n2. Pregnant women diagnosed with gestational diabetes mellitus\n3. Willing to participate in the study\n\nExclusion Criteria:\n\n1. Diagnosed with diabetes mellitus before pregnancy\n2. Allergic to materials such as tapes (e.g., redness, swelling, itching, pain, blisters, or rashes caused by breathable tapes or patches)\n3. Abnormal coagulation function",{"count":53,"type":21},[24],"This study aims to examine the effects of a lifestyle intervention based on a health belief model (HBM) supported by mobile health (mHealth) and the impact of continuous glucose monitoring (CGM) on maternal glycemic parameters, cardiometabolic risk, health behavior and infant's outcomes among women diagnosed with gestational diabetes mellitus (GDM).",[57,29],[57,29,59],{"date":287,"type":36},"2026-01-20",{"date":289,"type":36},"2024-11-11",{"date":66,"type":21},{"name":68,"class":43},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":44},"100613624","cgm-accuracy-in-pregnancy-study-100613624","NCT07269015","CGM Accuracy in Pregnancy Study","Evaluation of the Accuracy of Continuous Glucose Monitoring Systems and Educational Needs in Pregnant Women With Diabetes: A Comparison Between Dexcom One Plus and FreeStyle Libre 2 Plus","Inclusion Criteria:\n\n* Pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes, diagnosed before 32 weeks of gestation\n* Age ≥18 years\n* Willingness to wear two CGM systems simultaneously\n* Possession of a smartphone compatible with LibreLink\n* Ability to sign informed consent\n\nExclusion Criteria:\n\n* Comorbidities affecting glucose metabolism\n* Inability to use CGM devices or perform capillary glucose testing",{"count":300,"type":21},66,[24],"Pregnancy in women with diabetes remains a high-risk condition, requiring strict glycemic control due to rapid physiological changes that affect insulin sensitivity. Continuous glucose monitoring (CGM) provides detailed glucose trends, but the accuracy of newer, affordable systems such as Dexcom One Plus and FreeStyle Libre 2 Plus has not been evaluated during pregnancy.\n\nThis prospective interventional study aims to compare the accuracy of these two CGM systems-both worn simultaneously-using capillary glucose as the reference. The study also evaluates educational needs, skills, attitudes, digital competence, lifestyle habits, and patient-reported outcomes among pregnant women with type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes (GDM).",[304,29],"Pregestational Diabetes",[197,165,306],"pregnancy","2025-12-04",{"date":309,"type":36},"2025-12-08",{"date":311,"type":21},"2025-12",{"date":313,"type":21},"2027-01",{"name":315,"class":43},"Hospital Mutua de Terrassa",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":77,"minAge":18,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":44},"100465161","non-nutritive-sweetener-consumption-and-glucose-homeostasis-in-older-adults-with-prediabetes-100465161","NCT05337098","Non-Nutritive Sweetener Consumption and Glucose Homeostasis in Older Adults With Prediabetes","Non-Nutritive Sweetener Consumption (Aspartame and Sucralose) and Glucose Homeostasis in Older Adults With Prediabetes","Inclusion Criteria:\n\n* Age 40+ years\n* Prediabetic (fasting glucose concentration of 100-125 mg\u002FdL, 2-hour oral glucose tolerance test glucose concentration of 140-199 mg\u002FdL, or a HbA1c value of 5.7% to 6.4%)\n* Weight stable for previous 6 months (±2 kg)\n* BMI \\\u003C40 kg\u002Fm2\n* Sedentary to recreationally active\n* No plans to gain\u002Flose weight or change physical activity level\n* Willing to pick up food daily and consume foods provided for an 8-week period\n* Verbal and written informed consent\n* Approval by Medical Director\n* Consume less than one serving of non-nutritive sweetener per week\n\nExclusion Criteria:\n\n* BMI \\>40 kg\u002Fm2\n* Diabetes or diabetes medication\n* Antibiotic, prebiotic or prebiotic use in prior 3 months\n* Uncontrolled hypertension (blood pressure (BP) \\> 159\u002F99 mmHg)\n* Diagnosed inflammatory bowel disease\n* Past or current heart diseases, stroke, respiratory disease, endocrine or metabolic disease, or hematological-oncological disease\n* Vegetarian or vegan\n* Pregnant or plans to become pregnant\n* Breastfeeding\n* Food allergies or aversions, Phenylketonuria (PKU)\n* Estrogen or testosterone usage",{"count":186,"type":21},[24],"Animal and observational research in humans suggest that specific types of non-nutritive sweeteners (NNS) may impair glycemic control. However, whether NNS consumption impacts glucose homeostasis in middle-aged\u002Folder adults with prediabetes is unknown, and potential mechanisms by which this could occur have yet to be identified. The overall objective of this R21 proposal is to establish proof-of-concept for alterations in glucose homeostasis following intake of sucralose, but not aspartame, in middle-aged\u002Folder adults with prediabetes compared to a eucaloric diet with no NNS.",[29,327,328,329],"Oral Glucose Tolerance","Insulin Sensitivity","Inflammatory Markers","2025-12-03",{"date":307,"type":36},{"date":333,"type":36},"2023-04-18",{"date":335,"type":21},"2026-02-28",{"name":337,"class":43},"Virginia Polytechnic Institute and State University",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":77,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":44},"100594462","experience-with-the-use-of-continuous-glucose-monitoring-cgm-devices-in-people-with-type-2-diabetes-mellitus-100594462","NCT07019753","Experience With the Use of Continuous Glucose Monitoring (CGM) Devices in People With Type 2 Diabetes Mellitus","Glucocavi","Inclusion Criteria:\n\n* Have been using a CGM sensor daily for diabetes management for the past 12 months or more.\n* Treatment with intensive insulin therapy (basal bolus regimen with 3 or more daily doses of insulin).\n* Agree to participate in the study.\n\nExclusion Criteria:\n\n* Cognitive impairment measured by the SPMSQ test with a score of 3 or more errors.\n* Being institutionalised.\n* Have another person responsible for monitoring the device and making decisions related to diabetes (insulin adjustment, carbohydrate rations, etc.).\n* Language difficulty: not being able to hold a fluent conversation in Catalan or Spanish for 30-60 minutes.",{"count":346,"type":21},5,"Background: In recent years, diabetes management has evolved with the introduction of continuous glucose monitoring (CGM) devices. Some qualitative studies have been conducted to assess the experiences of patients with type 2 diabetes mellitus (T2DM) using CGM devices, but none have been conducted in a Mediterranean country. Furthermore, there are differences in the amount of time study participants used the CGM device, ranging from 14 days to 6 months, and in some studies, participants did not receive insulin treatment.\n\nObjectives: To understand the benefits and barriers described by people with type 2 diabetes mellitus who use CGM devices through inductive thematic analysis of interviews conducted with them.\n\nMethodology: Qualitative study with a phenomenological approach and conversational technique. Adults with T2DM who have used a CGM device continuously for the past 12 months will be interviewed individually.\n\nData analysis: They will be analyzed using inductive thematic analysis. The interviews will be transcribed verbatim, along with any relevant data collected by the other researcher present at the interview. Three researchers will then conduct a preliminary analysis, from which codes will be agreed upon and themes, categories, and subcategories will be proposed through triangulation among the researchers. This will be done inductively, through analysis, in-depth reflection, and debate among the three researchers.\n\nApplicability and relevance: Knowing the opinion of people with T2DM who use CGM devices, as well as the barriers and facilitators they find to its use will help healthcare professionals to better understand their patients and thus provide more personalised and closer healthcare. In addition, healthcare managers and administrators will be able to find out whether patients find it useful to use a CGM device, whether they reduce the use of capillary glycaemia strips, whether they become more aware of their disease and increase their self-monitoring, etc. All this will help to decide whether it is beneficial to extend the indication of these devices to more people with type 2 diabetes.",[349,29,221],"Patient Satisfaction",[29,349,221,351,352],"Quality of Life","Primary Care","2025-07-04",{"date":355,"type":36},"2025-07-09",{"date":357,"type":21},"2026-01",{"date":359,"type":21},"2026-10-31",{"name":361,"class":43},"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":77,"minAge":17,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":44},"100580555","cgm-in-icodextrin-pd-100580555","NCT06838819","CGM in Icodextrin PD","Evaluation of Accuracy of Medtronic Simplera™ CGM in Patients on Icodextrin-containing Peritoneal Dialysis Regimens","Inclusion Criteria:\n\n1. Type 1 or 2 diabetes mellitus for at least 3 months\n2. On continuous ambulatory peritoneal dialysis (CAPD) or APD for at least 2 months\n3. On icodextrin PD solutions for at least 1 month or planned for switching to icodextrin PD solutions within 3 months of screening\n4. Male or female age ≥ 18 years old and ≤ 75 year old.\n5. Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.\n6. Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.\n7. Willingness to abstain from swimming during their participation in the measurement phase.\n8. In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.\n9. Written informed consent to participate in the study provided by the patient.\n\nExclusion Criteria:\n\n1. Poorly controlled diabetes mellitus with HbA1c\\>11%\n2. Peritonitis within 1 month of screening\n3. Planned for switching to hemodialysis or living donor transplant in the future 1 month\n4. Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential\n5. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.\n6. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.\n7. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.\n8. Extensive skin changes\u002Fdiseases that preclude wearing the required number of devices on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).\n9. Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study.\n10. Blood donation of more than 500 ml within the last three months\n11. Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.\n12. Has a MRI scan, CT scan, or diathermy scheduled during the proposed study participation.\n13. An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).\n14. Women of reproductive potential who are unwilling to adopt contraceptive measures during the study period\n15. Patients with history of pacemaker and prosthesis implantation.\n16. Continuous use of real-time CGM for personal diabetes management in the three months prior to screening (sensor use \\>80% of time)","75 Years",{"count":186,"type":21},"Assessment of performance (precision and accuracy) of Simplera™ CGM as compared with a gold standard reference laboratory method (YSI glucose) in diabetes patients on peritoneal dialysis with icodextrin",[373,374,375,29],"Diabetes Mellitus (Diagnosis)","End Stage Renal Disease (ESRD)","Dialysis","2025-02-17",{"date":378,"type":36},"2025-02-21",{"date":380,"type":21},"2025-02-20",{"date":382,"type":21},"2026-09-20",{"name":384,"class":43},"Elaine Chow",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":77,"minAge":17,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":394,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":4},"100574169","effects-of-intraoperative-glycemic-management-strategies-assisted-with-rt-cgm-on-tir-and-postoperative-recovery-100574169","NCT06755788","Effects of Intraoperative Glycemic Management Strategies Assisted with RT-CGM on TIR and Postoperative Recovery","Effects of Intraoperative Glycemic Management Strategies Assisted with RT-CGM on TIR and Postoperative Recovery During Pancreaticoduodenectomy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18\n* Scheduled for pancreaticoduodenectomy\n* ASA classification I-III\n\nExclusion Criteria:\n\n* Emergency surgery\n* scheduled for MRI the day before surgery\n* Allergy to CGM sensor\n* Communication barriers or refusal to participate\n* BMI \\\u003C 18.5 kg\u002Fm²",{"count":393,"type":21},246,[24],"The purpose of this study is to investigate the effect of intraoperative blood glucose management based on real-time continuous glucose monitoring ( RT-CGM) on time in range (TIR) and postoperative recovery during pancreaticoduodenectomy. The primary outcome is intraoperative TIR. Additionally, it aims to compare the differences in other glucose metrics, quality of postoperative recovery, and 30-day postoperative complications and mortality between the two glycemic management methods .",[29],[398,399,400],"glycemic management","pancreaticoduodenectomy","time in range","2024-12-31",{"date":403,"type":36},"2025-01-01",{"date":405,"type":21},"2024-12-25",{"date":407,"type":21},"2025-12-31",{"name":409,"class":43},"Peking Union Medical College Hospital"]